Cargando…

Prediction of unresponsiveness to second intravenous immunoglobulin treatment in patients with Kawasaki disease refractory to initial treatment

PURPOSE: This study investigated predictors of unresponsiveness to second-line intravenous immunoglobulin (IVIG) treatment for Kawasaki disease (KD). METHODS: This was a single-center analysis of the medical records of 588 patients with KD who had been admitted to Asan Medical Center between 2006 an...

Descripción completa

Detalles Bibliográficos
Autores principales:	Seo, Euri, Yu, Jeong Jin, Jun, Hyun Ok, Shin, Eun Jung, Baek, Jae Suk, Kim, Young-Hwue, Ko, Jae-Kon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The Korean Pediatric Society 2016
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5099288/ https://www.ncbi.nlm.nih.gov/pubmed/27826327 http://dx.doi.org/10.3345/kjp.2016.59.10.408

Ejemplares similares

Diagnostic characteristics of supplemental laboratory criteria for incomplete Kawasaki disease in children with complete Kawasaki disease
por: Jun, Hyun Ok, et al.
Publicado: (2015)

Defining the risk of first intravenous immunoglobulin unresponsiveness in non-Asian patients with Kawasaki disease
por: Piram, Maryam, et al.
Publicado: (2020)

Intravenous immunoglobulin for the treatment of Kawasaki disease
por: Broderick, Cathryn, et al.
Publicado: (2023)

Risk Factors for Failure of Initial Intravenous Immunoglobulin Treatment in Kawasaki Disease
por: Cha, Sungho, et al.
Publicado: (2008)

Immunoglobulin profiling identifies unique signatures in patients with Kawasaki disease during intravenous immunoglobulin treatment
por: Ko, Tai-Ming, et al.
Publicado: (2018)

The Efficacy and Safety of High-Dose Intravenous Immunoglobulin in the Treatment of Kawasaki Disease: How Can We Predict Resistance to Intravenous Immunoglobulin Treatment of Kawasaki Disease?
por: Han, Ji Whan
Publicado: (2017)

Meta-analysis of factors predicting resistance to intravenous immunoglobulin treatment in patients with Kawasaki disease
por: Baek, Jin-Young, et al.
Publicado: (2016)

Intravenous Immunoglobulin Treatment in Kawasaki Disease Decreases the Incidence of Myopia
por: Yu, Hun-Ju, et al.
Publicado: (2021)

A low-frequency IL4R locus variant in Japanese patients with intravenous immunoglobulin therapy-unresponsive Kawasaki disease
por: Amano, Yuji, et al.
Publicado: (2019)

Diagnosis of Incomplete Kawasaki Disease in Infants Based on an Inflammation at the Bacille Calmette-Guérin Inoculation Site
por: Seo, Ji Hye, et al.
Publicado: (2012)

Randomized trial of different initial intravenous immunoglobulin regimens in Kawasaki disease
por: He, Lan, et al.
Publicado: (2021)

A decision tree model for predicting intravenous immunoglobulin resistance and coronary artery involvement in Kawasaki disease
por: Joung, Jinwoon, et al.
Publicado: (2022)

Parameters to Guide Retreatment After Initial Intravenous Immunoglobulin Therapy in Kawasaki Disease
por: Kim, Hyun Kwon, et al.
Publicado: (2011)

Peripheric arterial aneurisyms and monocytosis in intravenous immunoglobulin treatment resistant Kawasaki disease
por: Baskin, E, et al.
Publicado: (2008)

Thrombospondin-2 predicts response to treatment with intravenous immunoglobulin in children with Kawasaki disease
por: Yang, Shuai, et al.
Publicado: (2018)

Clinical Outcomes of Initial Dexamethasone Treatment Combined with a Single High Dose of Intravenous Immunoglobulin for Primary Treatment of Kawasaki Disease
por: Lim, Yun Ju, et al.
Publicado: (2014)

Relationship between vitamin D levels and intravenous immunoglobulin resistance in Kawasaki disease
por: Jun, Jae Sung, et al.
Publicado: (2017)

Corticosteroids Added to Initial Intravenous Immunoglobulin Treatment for the Prevention of Coronary Artery Abnormalities in High‐Risk Patients With Kawasaki Disease
por: Ae, Ryusuke, et al.
Publicado: (2020)

Detection rate and clinical impact of respiratory viruses in children with Kawasaki disease
por: Kim, Ja Hye, et al.
Publicado: (2012)

Effectiveness of Medium-Dose Intravenous Immunoglobulin (1 g/kg) in the Treatment of Kawasaki Disease
por: Yeo, Joong-Seok, et al.
Publicado: (2010)

Infliximab Treatment for Intravenous Immunoglobulin-resistant Kawasaki Disease: a Multicenter Study in Korea
por: Hur, Gyu, et al.
Publicado: (2018)

Comparison of the Laboratory Data Between Kawasaki Disease and Enterovirus After Intravenous Immunoglobulin Treatment
por: Lin, Li-Yan, et al.
Publicado: (2012)

Predictors of nonresponse to intravenous immunoglobulin therapy in Kawasaki disease
por: Park, Hyo Min, et al.
Publicado: (2013)

Predictors and management of intravenous immunoglobulin-resistant Kawasaki disease
por: Song, Min Seob
Publicado: (2019)

Kawasaki disease: Aetiopathogenesis and therapeutic utility of intravenous immunoglobulin
por: Galeotti, Caroline, et al.
Publicado: (2010)

Predictors for Intravenous Immunoglobulin Resistance in Patients with Kawasaki Disease
por: Li, Wei, et al.
Publicado: (2022)

Intravenous Immunoglobulin in Kawasaki Disease—Evolution and Pathogenic Mechanisms
por: Nadig, Pallavi L., et al.
Publicado: (2023)

Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Ma, Yongmei, et al.
Publicado: (2022)

Comparison of Machine Learning Models for Prediction of Initial Intravenous Immunoglobulin Resistance in Children With Kawasaki Disease
por: Kuniyoshi, Yasutaka, et al.
Publicado: (2020)

Two PerPLEXing Cases of Hashimoto’s Encephalopathy Unresponsive to Steroid and Intravenous Immunoglobulin Therapy
por: Karan, Abhinav, et al.
Publicado: (2022)

Coronary artery status of patients with transient fever 24–36 h after first IVIG infusion did not differ from that seen in responsive patients
por: Baek, Jae Suk, et al.
Publicado: (2018)

Treatment Response in Kawasaki Disease Is Associated with Sialylation Levels of Endogenous but Not Therapeutic Intravenous Immunoglobulin G
por: Ogata, Shohei, et al.
Publicado: (2013)

FCGR2A Promoter Methylation and Risks for Intravenous Immunoglobulin Treatment Responses in Kawasaki Disease
por: Kuo, Ho-Chang, et al.
Publicado: (2015)

Crucial transcripts predict response to initial immunoglobulin treatment in acute Kawasaki disease
por: Geng, Zhimin, et al.
Publicado: (2020)

Prediction of Resistance to Standard Intravenous Immunoglobulin Therapy in Kawasaki Disease
por: Lee, Sang Min, et al.
Publicado: (2014)

Hemolysis From Intravenous Immunoglobulin in Obese Patients With Kawasaki Disease
por: Van Anh, Khanh-Van Y., et al.
Publicado: (2020)

Prediction of repeated intravenous immunoglobulin resistance in children with Kawasaki disease
por: Lu, Yaheng, et al.
Publicado: (2021)

Retracted: Efficacy of Glucocorticoid plus Intravenous Immunoglobulin in Children with Immunoglobulin-Insensitive Kawasaki Disease
por: Healthcare Engineering, Journal of
Publicado: (2023)

Systemic lupus erythematosus with refractory ulcerated livedoid vasculopathy: Successful treatment with intravenous immunoglobulin and warfarin
por: Yoshioka, Katsunobu, et al.
Publicado: (2018)

Late-onset and long-term systemic dyshidrotic eczema after intravenous immunoglobulin treatment for Kawasaki disease
por: Yokoyama, Koji, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_rkq8sg5kpt5fsmu4qdfl7irpnf